Liglinra

Linagliptin, the active ingredient in Liglinra, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control when used with diet and exercise.

GNH USA supplies Liglinra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liglinra, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when combined with metformin or other oral agents. - Type 2 diabetes mellitus (lifestyle adjunct): supports diet and exercise interventions to achieve target HbA1c.

Common side effects are generally mild and transient.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: occasional mild to moderate headache. - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Dizziness: transient light‑headedness. - Upper respiratory infection: cough or sore throat. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Acute renal failure: sudden decrease in urine output. - Cardiovascular events: rare reports of myocardial infarction.

Linagliptin should be used with clinical vigilance in specific patient groups.

- Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver enzymes in patients with existing liver disease. - Elderly patients: start at the recommended dose and monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: avoid use unless the potential benefit outweighs the risk; data are limited. - Concomitant hypoglycaemic agents: adjust dose of insulin or sulfonylureas to reduce hypoglycaemia risk. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture.

Linagliptin may interact with several drug classes; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Strong P‑glycoprotein inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure. - Combined use with insulin or sulfonylureas without dose adjustment: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Metformin: monitor renal function as both are renally excreted. - Diuretics (e.g., thiazides): may affect glucose control. - ACE inhibitors or ARBs: watch for additive blood pressure effects. - Rifampin: may reduce linagliptin plasma concentrations. - Anticoagulants: monitor INR if used concurrently.